Vivian Fonseca, MD, is professor of medicine, assistant dean for clinical research, and the Tullis-Tulane Alumni Chair in Diabetes at Tulane University School of Medicine.

CAPTAIN-T2D: New Trial Investigates Treating Elevated Cortisol in T2D, With Vivian Fonseca, MD

The phase 2 Clofutriben And Placebo Against INtractable Type 2 Diabetes (CAPTAIN-T2D) trial, investigating clofutriben to improve glycemic control and metabolic health in patients with difficult-to-control 

 and elevated cortisol, has officially enrolled its first patient.

CAPTAIN-T2D directly follows positive results from the CATALYST trial in 2025, which saw 136 patients with T2D and hypercortisolism randomly assigned in a 2:1 ratio to either mifepristone 300-900 mg once daily (n = 91) or placebo (n = 45) for 24 weeks. The primary endpoint was the change in HbA1c, which worked out to a -1.32% difference compared to placebo. Additionally, patients receiving mifepristone saw reductions in body weight and waist circumference.

“So, what we want to do now in CAPTAIN-T2D is to use another approach at treating this elevated cortisol,” Vivian Fonseca, MD, professor of medicine, assistant dean for clinical research, and the Tullis-Tulane Alumni Chair in Diabetes at Tulane University School of Medicine, told 

 in an exclusive interview. “In this instance, we’re using an 11-beta hydroxysteroid dehydrogenase inhibitor, which uses a completely different approach from mifepristone. You’re addressing intracellular cortisol by blocking this enzyme that leads to conversion of the inactive cortisone to cortisol, and so you’re decreasing cortisol activity in the tissues.”

CAPTAIN-T2D is a 2-part trial – the first part will see patients with poorly controlled T2D despite being on multiple medications screened for elevated cortisol using an overnight dexamethasone suppression test. This period will last between 5 and 9 weeks for most participants.

Eligible patients will then be randomly assigned to either clofutriben 0.2 mg, 2 mg, 6 mg, or 12 mg, or a placebo control, all of which will be administered daily. This second part will last for 24 weeks, with a follow-up phone call 4 weeks after the final dose.

To be eligible for inclusion, patients must be ≥18 years old with an HbA1c ≥7.5% documented within 3 months prior to screening. Additionally, patients require ≥1 of the following:

Diabetes complications – retinopathy, nephropathy, neuropathy, 

Hypertension needing ≥2 adequately dosed AHMs

Adequately dosed basal or basal plus prandial insulin on top of ≥1 other ADM

Adequately dosed incretin agonists on top of ≥1 other ADM

Evidence or history of osteoporosis or non-traumatic fracture

Established diagnosis of a neoplastic source of hypercortisolism and have failed, are ineligible for, or declined surgery.

CAPTAIN-T2D has 2 primary endpoints: the first is the percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >-140 ng/dL after a single dexamethasone 1 mg dose taken the night prior. The second endpoint involves glycated hemoglobin A1c percent change from baseline to week 24 by treatment. Secondary endpoints include fasting plasma glucose change from baseline and the frequency of treatment-emergent adverse events.

The trial is expected to enroll a total of 1500 patients and is planned to end in June of 2028.

“We’ve begun to use this method a lot in other conditions, such as cancer: you find a particular defect, and you treat it with therapy that’s specifically targeted to that defect,” Fonseca said. “Unfortunately, we don’t have much of that in diabetes. We’ve been using a one-glove-fits-all approach, giving everybody every new medication that comes along, and the success has been mixed. Overall, control is better than it was 20 years ago, but it’s still not right, and I think identifying abnormalities could help with better outcomes.”

Editor’s Note: Fonseca reports disclosures with Abbott, AstraZeneca, Novo Nordisk, Sanofi-Aventis, Eli Lilly, Bayer, and others.

Sparrow Pharmaceuticals. Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluation Clofutriben for Difficult-to-Control Type 2 Diabetes. 

. January 6, 2026. Accessed January 23, 2026. 

https://www.biospace.com/press-releases/sparrow-pharmaceuticals-announces-first-patient-enrolled-in-phase-2b-clinical-trial-evaluating-clofutriben-for-difficult-to-control-type-2-diabetes

DeFronzo RA, Fonseca V, Aroda VR, et al. Inadequately controlled type 2 diabetes and hypercortisolism: Improved glycemia with mifepristone treatment. 

Sparrow Pharmaceuticals. Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) (CAPTAIN-T2D). ClinicalTrials.gov Identifier: NCT07296484. Updated January 22, 2026. Accessed January 23, 2026. 

https://clinicaltrials.gov/study/NCT07296484?term=NCT07296484&rank=1

Videos

Fonseca explains the structure and goals of the ongoing trial, which has enrolled its first patient to clofutriben treatment against hard-to-control T2D.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Autoclaved Peanuts Reduce IgE Binding, Improve Tolerability, With Casey Cohen, PhD

Heat- and pressure-based food processing is not new to allergy research, but new data suggest it may meaningfully alter peanut allergenicity in ways that traditional cooking cannot. In a recent interview with 

, Casey Cohen, PhD, of McGill University, discussed findings from a study demonstrating that autoclaving peanuts, a process combining high temperature, pressure, and moisture, substantially reduces immunoglobulin E (IgE) binding and improves oral tolerability in individuals with a 

“The way people eat peanuts is often roasted peanuts if they're eating peanut butter or just roasted peanuts,” Cohen said. “Or sometimes they boil peanuts in different places of the world, often in Asia. Autoclaving is rather untraditional…the process of autoclaving is used for sterilization. What we found is that it's actually changing the proteins in a different way. It's not just using heat, but the presence of water is changing them differently. It’s actually taking these proteins, breaking them down, not completely, but enough, where we have a lot of fragments, and we think that that is what is introducing different forms of peanut proteins to the immune system. That is not happening with say, boiled or roasted peanut.”

The study evaluated how autoclaving peanuts at 130°C and 2.4 atmospheres for 30 minutes alters peanut proteins compared with raw or roasted preparations. Using mass spectrometry-based proteomics, the investigators showed that autoclaving extensively fragments major peanut allergens, including Ara h 1 and Ara h 2, and completely degrades Ara h 8. These molecular changes translated into a 74% reduction in peanut-specific IgE binding in sera from highly allergic patients compared with raw peanuts.

Clinically, the effects were notable. In skin prick testing of 41 peanut-allergic participants, autoclaved peanut extract produced significantly smaller wheal sizes than standard commercial extract (median 5 mm vs 10 mm; 

 <.001). Although responses were heterogeneous, patients with the greatest wheal size reductions tended to have lower IgE levels to peanut (

 <.05), suggesting a potential role for autoclaved extracts in phenotyping peanut allergy risk. However, Cohen said this remains exploratory.

All 10 peanut-allergic participants undergoing an oral food challenge (OFC) tolerated the maximum cumulative dose of autoclaved peanut (444 mg), equivalent to ≥ 1 whole peanut, with only mild to moderate symptoms. In contrast, all participants reacted to blanched peanuts at much lower doses (median 9 mg), often requiring treatment, including epinephrine.

Cohen cautioned clinicians against extrapolating these findings directly to patient practice. Autoclaved peanuts are not ready for home use, nor should patients attempt self-experimentation. It is uncertain whether any patient with a food allergy can tolerate autoclaved peanuts.

“What is more interesting, we believe, is that we can actually use this autoclave peanut as a starting substrate for immunotherapy,” Cohen said. “Right now, a lot of people who are allergic to peanuts severely will have to start with incredibly small amounts of peanuts. It's… smaller than my pinky nail. In that case, it's hard to be consistent. We get a lot of variability, and the peanut proteins themselves are a lot more rigid and [a] lot more likely to induce a more dangerous reaction. By autoclaving the peanuts, we think it'll give us more leeway. We can start at a higher dose of autoclaving peanuts, especially if there's no dangerous symptoms coming with it, and then we can work our way up to maybe, eventually, transfer over to the regular, traditional peanut.”

Cohen CG, Toscano-Rivero D, Ahmed EA, et al. Autoclaved Peanuts Exhibit Reduced Immunoglobulin E Binding and Improved Oral Tolerability. 

. Published online January 6, 2026. doi:10.1111/all.70208

New data show heat- and pressure-treated peanuts significantly reduce IgE binding, skin test reactivity, and oral challenge severity in allergic patients.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Kristi B. Hawley, DO, is the founder and owner of The Derm Institute of West Michigan.

The Medical Sisterhood: Advocacy and Systemic Change, With Kristi Hawley, DO

 in January 2026 opens with a candid and timely conversation about advocacy, autonomy, and the quiet breaking points many women physicians experience within modern medicine. Hosted by Mona Shahriari, MD, of Yale School of Medicine, the episode features Kristi B. Hawley, DO, founder and owner of The Derm Institute of West Michigan, whose journey as a dermatologist, practice owner, and physician advocate offers a powerful lens into the systemic challenges facing clinicians today.

Rather than framing the new year around resolutions or productivity goals, Shahriari sets the tone by addressing a reality familiar to many women in medicine: the feeling that January simply brings renewed pressure from a system that continues to demand more while offering less control. Hawley shares how her own advocacy journey began not from ambition, but from frustration and moral distress early in her career. After joining a practice where patient care conflicted with her values, she describes the emotional toll of witnessing care that felt misaligned with her ethics, and the sleepless nights that followed.

Opening her own practice in 2019 provided a degree of autonomy, but Hawley quickly realized that independence alone did not shield her from larger systemic forces. Insurance barriers, pharmacy benefit managers, reimbursement cuts, and corporate medicine continued to dictate patient access to care, often leaving physicians blamed for decisions they do not control. This realization marked a turning point, pushing Hawley to move beyond venting privately and toward advocacy at the state and national levels.

Throughout the conversation, Shahriari and Hawley unpack the misconception that physicians are the primary drivers of rising healthcare costs, noting how patients often perceive doctors as gatekeepers rather than allies. Both emphasize the importance of patient advocacy alongside physician advocacy, highlighting how patient voices can resonate more strongly with lawmakers than professional lobbying alone. Their shared experiences working with dermatology advocacy organizations underscore the power of bringing patient stories directly to Capitol Hill.

The episode also explores the gendered dynamics of advocacy. Hawley reflects on how women are often socialized to remain agreeable and quiet, and how speaking assertively, whether in the exam room or legislative settings, can be perceived differently when voiced by women. She candidly discusses the confidence it took to overcome fears of being labeled “too loud” or “difficult,” emphasizing that advocacy does not require aggression, but does require persistence and self-trust.

Importantly, the discussion demystifies advocacy by addressing its “unsexy” realities. Hawley shares how political engagement is often slow, frustrating, and deeply influenced by financial power. Still, she stresses that small actions, joining professional organizations, donating modestly to PACs, responding to advocacy emails, and participating in state-level efforts, can collectively drive meaningful change.

As the episode closes, both physicians underscore that burnout is not always about workload, but about powerlessness. Advocacy, even in small forms, can restore a sense of agency and purpose. Hawley leaves listeners with a resonant message: there is more than one seat at the table, and progress depends on women lifting one another rather than competing. Together, Shahriari and Hawley reaffirm 

’s mission—to create space for honest dialogue, shared strength, and collective action among women physicians.

Editor’s note: This summary was edited with the help of AI tools.

Want to join The Medical Sisterhood community? Click here to join our LinkedIn Group!

This first episode of 2026 highlights ways to advocate for change in healthcare, empowering each other and patients while navigating systemic challenges.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Spyridon Fortis, MD, from the division of pulmonary, critical care, and occupational medicine at the University of Iowa Hospital and Clinics.

Bronchodilator Response Predicts COPD Risk, With Spyridon Fortis, MD

Bronchodilator responsiveness has traditionally been associated with 

, often leading clinicians to consider asthma-COPD overlap when airflow limitation is observed. However, in 

, Spyridon Fortis, MD, of the University of Iowa Hospital and Clinics, said that this perspective may overlook the broader prognostic value of bronchodilator response, particularly in smokers with preserved spirometry.

“A lot of people…use the bronchodilator response stimulus as a [criterion]… to say, ‘Oh, my patient has asthma,’ or ‘My patient has…COPD.’ Bronchodilator responsiveness [is] actually [a] diagnostic [criterion] to demonstrate lung function viability in asthma. In COPD, [it] has no role, and it should not be used to distinguish the two diseases,” Fortis said. “It's very common to have bronchodilator responsiveness [in both] COPD and asthma…it shouldn't play any role to say my patient has asthma-COPD, asthma-COPD overlap. I don't even like the term [of asthma-COPD overlap]. Every year, [I] teach medical students, [it is] very difficult [for them] to accept that bronchodilator responsiveness cannot distinguish the two diseases.”

Fortis and colleagues conducted the COPDGene analysis, a cross-sectional study evaluating whether genetic predisposition to 

 is associated with bronchodilator responsiveness and whether these factors independently or jointly influence lung function decline among individuals at risk for COPD.

 The study included 4824 adults aged 45 to 80 years with ≥ 10 pack-year smoking history and normal baseline spirometry. Bronchodilator responsiveness, measured as the percent change in forced expiratory volume in 1 second (FEV₁) after bronchodilator administration, was compared with polygenic risk scores to determine which better predicted long-term lung function decline and COPD development.

Across racial groups, bronchodilator responsiveness consistently outperformed genetic risk scores, demonstrating higher predictive accuracy for FEV₁ decline and progression to COPD. Genetic risk was correlated with bronchodilator response only in non-Hispanic White participants, not in African American participants.

During the interview, Fortis emphasized that bronchodilator responsiveness should not be used to distinguish asthma from COPD. While it remains a diagnostic criterion for asthma, in COPD it primarily reflects airway pathology. such as inflammation and smooth muscle constriction, rather than disease classification. The study supports this view, showing that even among individuals with normal spirometry, bronchodilator responsiveness identifies subclinical airway disease that may signal future lung function decline.

The analysis also highlighted the challenges of applying rigid thresholds for bronchodilator response. Historical guidelines define responsiveness using different criteria, but no single cutoff reliably stratifies long-term risk. Responsiveness can vary over time, influenced by disease activity and airway inflammation. Nevertheless, greater responsiveness consistently correlated with faster FEV₁ decline, underscoring its value as a prognostic marker rather than a diagnostic test.

Fortis noted that interventional studies are needed to determine whether early treatment in individuals with preserved lung function and significant bronchodilator responsiveness could slow or prevent COPD progression. If successful, such studies could shift clinical practice toward earlier risk identification and proactive intervention, moving COPD care beyond traditional diagnostic frameworks and leveraging bronchodilator responsiveness as a tool for prevention rather than classification.

“If we test and prove…that existing treatment in people with bronchodilator response [and] normal spirometry can prevent them [from losing] lung function, that can change [our] practice…and that will be a new focus,” Fortis said.

Derman C. Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression. HCPLive. Published on January 14, 2026. Accessed on January 22, 2026. 

https://www.hcplive.com/view/bronchodilator-response-outperforms-genetic-risk-predicting-copd-progression

Fortis S, Comellas AP, Bowler RP, et al. Relationships between bronchodilator responsiveness, a COPD polygenic risk score, and COPD progression. Respir Med. Published online January 9, 2026

Fortis discusses new data that challenge the use of bronchodilator response as a tool for distinguishing asthma from COPD.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Results from 2 global phase 3 studies suggest amliteli­mab therapy may offer clinical benefit for individuals with 

, although prespecified secondary endpoints, including measures of erythema, were not met in all analyses.

These new results were announced by Sanofi on January 23. Encouraging findings from the 

 (NCT06130566) had been reported in September 2025.

 The new data resulted from 2 additional global phase 3 studies, namely SHORE (NCT06224348) and COAST 2 (NCT06181435), strengthening the evidence base supporting amlitelimab as a potential medication option for adolescents and adults with atopic dermatitis.

"Importantly, these results validate amlitelimab’s novel mechanism of action to block OX40-ligand without T-cell depletion and its promise to normalize the immune system over time," Houman Ashrafian, executive vice president and head of Research & Development at Sanofi, said in a statement.

Amlitelimab is a fully human monoclonal antibody designed not to deplete T cells, selectively targeting OX40 ligand (OX40L). OX40L is an important regulator of immune activation, and this inhibition of OX40L signaling early in the inflammatory cascade is designed to modulate excessive T-cell–driven inflammation while also preserving immune cell populations.

The SHORE and COAST 2 studies evaluated efficacy at the 24-week mark in patients with moderate-to-severe disease who were treated with amlitelimab every 4 weeks (Q4W) or every 12 weeks (Q12W). The primary endpoint for the US and US reference countries, was the proportion of participants attaining a validated Investigator Global Assessment for AD (vIGA-AD) score of 0 or 1, with at least an improvement of 2 points from baseline. This was analyzed via non-responder imputation. Within the European Union, EU reference countries, and Japan, the studies’ co-primary endpoints included the same vIGA-AD response as well as attainment a 75% improvement at least in the Eczema Area and Severity Index (EASI-75).

The SHORE trial was a randomized, double-blind, placebo-controlled, 3-arm phase 3 analysis involving 596 patients aged 12 years and older. Those evaluated were given amlitelimab Q4W or Q12W in combination with medium-potency topical corticosteroids, with or without the use of topical calcineurin inhibitors. By the 24-week mark, both amlitelimab regimens had met all of the studies’ primary and key secondary endpoints versus placebo across US and EU analyses.

COAST 2 involved a similar design, with 547 participants treated with amlitelimab as monotherapy. Both dosing schedules used in this study in the US and US reference countries also met their primary endpoint at Week 24 as opposed to placebo. However, a key secondary endpoint assessing vIGA-AD 0/1 with barely perceptible erythema did not attain statistical significance. Within EU and EU reference regions, neither regimen was successful in attaining statistical significance for the co-primary vIGA-AD and EASI-75 endpoints. Subsequent secondary endpoint 

Findings related to safety were comparable between amlitelimab and placebo in both trials. In SHORE, the most frequently reported treatment-emergent adverse events (TEAEs) included upper respiratory tract infection (7.9% versus 4.4%), nasopharyngitis (9.5% with amlitelimab versus 12.5% with placebo), and atopic dermatitis (2.7% versus 5.6%). In the COAST 2 trial, common TEAEs were upper respiratory tract infection (4.8% versus 4.0%), nasopharyngitis (5.9% versus 7.4%), and atopic dermatitis (5.3% versus 2.7%).

Sanofi’s release described rates of serious AEs and discontinuations as similar between treatment and placebo arms in both studies. Additional long-term data were drawn from a preliminary analysis of the ongoing open-label ATLANTIS phase 2 study (NCT05769777). This phase 2 trial followed 591 subjects provided amlitelimab treatment Q4W through Week 52. Findings highlighted indicated continued improvements in skin clearance and atopic dermatitis severity beyond the 24-week mark, with strong tolerability.

The most common TEAEs were headache (10.3%), nasopharyngitis (19.1%), influenza (9.1%), upper respiratory tract infection (7.2%), atopic dermatitis (8.6%), and accidental overdose connected to scheduling errors (5.1%). Serious adverse events occurred in 4.7% of patients, and 2.9% discontinued treatment. One case of cutaneous Kaposi’s sarcoma was reported in an individual with known risk factors, leading to treatment cessation; the patient was described as recovering.

"The totality of data seen to date reinforce our confidence in amlitelimab’s potential to deliver both Q12W dosing from the start and progressive efficacy through Week 52,” Ashrafian said in a statement.

 “We look forward to sharing additional results, including longer-term data, as we move toward global regulatory submissions.”

The results from COAST 1, COAST 2, SHORE, and the interim ATLANTIS analysis are slated to be presented during upcoming medical conferences.

Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis. Sanofi. January 23, 2026. 

https://www.sanofi.com/en/media-room/press-releases/2026/2026-01-23-06-00-00-3224400

Smith T. Phase 3 Data Show Amlitelimab Effective in Adults, Adolescents with Atopic Dermatitis. HCPLive. September 4, 2025. Accessed January 23, 2026. 

https://www.hcplive.com/view/phase-3-data-amlitelimab-effective-adults-adolescents-atopic-dermatitis

Articles

Amlitelimab has shown efficacy and safety in treating moderate-to-severe atopic dermatitis in patients aged 12 and older, as demonstrated in two global phase 3 studies, SHORE and COAST 2. These studies confirmed amlitelimab's novel mechanism of action, targeting OX40 ligand without depleting T cells. Both studies met primary endpoints in the US, but COAST 2 did not achieve statistical significance for some endpoints in the EU. Safety profiles were comparable to placebo, with common adverse events including upper respiratory infections and nasopharyngitis. Long-term data from the ATLANTIS phase 2 study indicated continued efficacy and tolerability.

However, key secondary endpoints, including measures of erythema, were not met in all analyses.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

Ahmad Masri, MD, MS, is the director of the Hypertrophic Cardiomyopathy Center at Oregon Health and Science University. 

Maron and Masri discuss whether myosin inhibitors, particularly aficamten, should be considered first-line therapy for symptomatic obstructive HCM in treatment-naive patients, in light of data from trials like MAPLE-HCM.

Video Series

Positioning Cardiac Myosin Inhibitors as First-Line Therapy: Evidence Versus Beta-blockers

Maron and Masri review pivotal phase 3 trials of mavacamten and aficamten and explain how efficacy and systolic function monitoring shaped their respective REMS programs.

Phase 3 Evidence and Safety Framework for Myosin Inhibitors: EXPLORER, VALOR, SEQUOIA, and REMS

Maron and Masri introduce cardiac myosin inhibitors—mavacamten and aficamten—explaining their sarcomere-level mechanism and the rationale for targeting hypercontractility in obstructive HCM.

Cardiac Myosin Inhibitors in Obstructive HCM: Mechanism, Regulatory Milestones, and Clinical Rationale

Maron and Masri review decades of experience with beta-blockers, calcium channel blockers, disopyramide, and septal reduction therapies, underscoring persistent under-treatment and the unmet need that set the stage for myosin inhibitors.

Historical Management of Obstructive HCM: Limitations of Medical Therapy and Septal Reduction Access

Albert Rizzo, MD, is the chief medical officer of the American Lung Association.

Lungcast reflects on pulmonology in 2025, looking back at topics ranging from ALA's ‘State of the Air’ report to the lung-gut microbiome.



Strategic Alliance Partnership

Lungcast

Join the American Lung Association and HCPLive every month as Dr. Al Rizzo interviews world-leading experts on the great challenges, accomplishments, and stories in respiratory medicine.

The Lungcast 2025 Recap

Experts Discuss the REPLENISH Trial for Polymyalgia Rheumatica 

Howa Yeung, MD MSc is an associate professor of Dermatology at the Emory University School of Medicine.

In this Q&A interview with Yeung, a discussion was conducted regarding newly-released findings on acne in patients identifying as transgender.

Acne

The HCPLive acne page is a resource for medical news and expert insights on dermatological disease. This page features expert-led coverage, articles, videos, and research on the therapies and development of treatments for chronic acne, and more.

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

The Trial Design and Interim Results From the GCAptAIN Trial 

In this opening segment, Martin (Marty) Maron, MD, and Ahmed Masri, MD, PA-C, introduce the discussion and frame obstructive hypertrophic cardiomyopathy (HCM) as the central focus, emphasizing outflow tract gradients as the key driver of symptoms.

Framing Obstructive Hypertrophic Cardiomyopathy: Epidemiology, Pathophysiology, and Clinical Focus

Nada Elbuluk, MD, MSc, is a dermatologist in California. 

This segment of the latest Skin of Color Savvy episode highlights a conversation between Nada Elbuluk, MD, MSc, and Michelle Rodrigues, MBBS.

Latest News

CAPTAIN-T2D: New Trial Investigates Treating Elevated Cortisol in T2D, With Vivian Fonseca, MD

Autoclaved Peanuts Reduce IgE Binding, Improve Tolerability, With Casey Cohen, PhD

The Medical Sisterhood: Advocacy and Systemic Change, With Kristi Hawley, DO

Bronchodilator Response Predicts COPD Risk, With Spyridon Fortis, MD

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older